Keep Us Strong WikiLeaks logo

Currently released so far... 97115 / 251,287

Articles

Browse latest releases

Browse by creation date

Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z

Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
ETRD EAGR ETTC EAID ECON EFIN ECIN EINV ELAB EAIR ENRG EPET EWWT ECPS EIND EMIN ELTN EC ETMIN EUC EZ ET ELECTIONS ENVR EU EUN EG EINT ER ECONOMICS ES EMS ENIV EEB EN ECE ECOSOC EK ENVIRONMENT EFIS EI EWT ENGRD ECPSN EXIM EIAD ERIN ECPC EDEV ENGY ECTRD EPA ESTH ECCT EINVECON ENGR ERTD EUR EAP EWWC ELTD EL EXIMOPIC EXTERNAL ETRDEC ESCAP ECO EGAD ELNT ECONOMIC ENV ETRN EIAR EUMEM ENRGPARMOTRASENVKGHGPGOVECONTSPLEAID EREL ECOM ECONETRDEAGRJA ETCC ETRG ECONOMY EMED ETR ENERG EITC EFINOECD EURM EENG ERA EXPORT ENRD ECONEINVETRDEFINELABETRDKTDBPGOVOPIC EGEN EBRD EVIN ETRAD ECOWAS EFTA ECONETRDBESPAR EGOVSY EPIN EID ECONENRG EDRC ESENV ETT EB ENER ELTNSNAR ECHEVARRIA ETRC EPIT EDUC ESA EFI ENRGY ESCI EE EAIDXMXAXBXFFR EETC ECIP EIAID EIVN EBEXP ESTN EING EGOV ETRA EPETEIND ELAN ETRDGK EAIDRW ETRDEINVECINPGOVCS EPEC ENVI ELN EAG EPCS EPRT EPTED ETRB EUM EAIDS EFIC EFINECONEAIDUNGAGM EAIDAR ESF EIDN ELAM EDU EV EAIDAF ECN EDA EXBS EINTECPS ENRGTRGYETRDBEXPBTIOSZ EPREL EAC EINVEFIN ETA EAGER EINDIR ECA ECLAC ELAP EITI EUCOM ECONEFINETRDPGOVEAGRPTERKTFNKCRMEAID EARG ELDIN EINVKSCA ENNP EFINECONCS EFINTS ECCP ETC EAIRASECCASCID EINN ETRP EAIDNI EFQ ECOQKPKO EGPHUM EBUD ECONEINVEFINPGOVIZ ENERGY ELB EINDETRD EMI ECONEFIN EIB EURN ETRDEINVTINTCS EIN EFIM ETIO ELAINE EMN EATO EWTR EIPR EINVETC ETTD ETDR EIQ ECONCS EPPD ENRGIZ EISL ESPINOSA ELEC EAIG ESLCO EUREM ENTG ERD EINVECONSENVCSJA EEPET EUNCH ECINECONCS ETRO ETRDECONWTOCS ECUN EFND EPECO EAIRECONRP ERGR ETRDPGOV ECPN ENRGMO EPWR EET EAIS EAGRE EDUARDO EAGRRP EAIDPHUMPRELUG EICN ECONQH EVN EGHG ELBR EINF EAIDHO EENV ETEX ERNG ED
KMDR KPAO KPKO KJUS KCRM KGHG KFRD KWMN KDEM KTFN KHIV KGIC KIDE KSCA KNNP KHUM KIPR KSUM KISL KIRF KCOR KRCM KPAL KWBG KN KS KOMC KSEP KFLU KPWR KTIA KSEO KMPI KHLS KICC KSTH KMCA KVPR KPRM KE KU KZ KFLO KSAF KTIP KTEX KBCT KOCI KOLY KOR KAWC KACT KUNR KTDB KSTC KLIG KSKN KNN KCFE KCIP KGHA KHDP KPOW KUNC KDRL KV KPREL KCRS KPOL KRVC KRIM KGIT KWIR KT KIRC KOMO KRFD KUWAIT KG KFIN KSCI KTFIN KFTN KGOV KPRV KSAC KGIV KCRIM KPIR KSOC KBIO KW KGLB KMWN KPO KFSC KSEAO KSTCPL KSI KPRP KREC KFPC KUNH KCSA KMRS KNDP KR KICCPUR KPPAO KCSY KTBT KCIS KNEP KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KNNB KGCC KINR KPOP KMFO KENV KNAR KVIR KDRG KDMR KFCE KNAO KDEN KGCN KICA KIMMITT KMCC KLFU KMSG KSEC KUM KCUL KMNP KSMT KCOM KOMCSG KSPR KPMI KRAD KIND KCRP KAUST KWAWC KTER KCHG KRDP KPAS KITA KTSC KPAOPREL KWGB KIRP KJUST KMIG KLAB KTFR KSEI KSTT KAPO KSTS KLSO KWNN KPOA KHSA KNPP KPAONZ KBTS KWWW KY KJRE KPAOKMDRKE KCRCM KSCS KWMNCI KESO KWUN KPLS KIIP KEDEM KPAOY KRIF KGICKS KREF KTRD KFRDSOCIRO KTAO KJU KWMNPHUMPRELKPAOZW KEN KO KNEI KEMR KKIV KEAI KWAC KRCIM KWCI KFIU KWIC KCORR KOMS KNNO KPAI KBWG KTTB KTBD KTIALG KILS KFEM KTDM KESS KNUC KPA KOMCCO KCEM KRCS KWBGSY KNPPIS KNNPMNUC KWN KERG KLTN KALM KCCP KSUMPHUM KREL KGH KLIP KTLA KAWK KWMM KVRP KVRC KAID KSLG KDEMK KX KIF KNPR KCFC KFTFN KTFM KPDD KCERS KMOC KDEMAF KMEPI KEMS KDRM KEPREL KBTR KEDU KNP KIRL KNNR KMPT KISLPINR KTPN KA KJUSTH KPIN KDEV KTDD KAKA KFRP KWNM KTSD KINL KJUSKUNR KWWMN KECF KWBC KPRO KVBL KOM KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KEDM KFLD KLPM KRGY KNNF KICR KIFR KM KWMNCS KAWS KLAP KPAK KDDG KCGC KID KNSD KMPF KPFO KDP KCMR KRMS KNPT KNNNP KTIAPARM KDTB KNUP KPGOV KNAP KNNC KUK KSRE KREISLER KIVP KQ KTIAEUN KPALAOIS KRM KISLAO KWM KFLOA
PHUM PINR PTER PGOV PREL PREF PL PM PHSA PE PARM PINS PK PUNE PO PALESTINIAN PU PBTS PROP PTBS POL POLI PA PGOVZI POLMIL POLITICAL PARTIES POLM PD POLITICS POLICY PAS PMIL PINT PNAT PV PKO PPOL PERSONS PING PBIO PH PETR PARMS PRES PCON PETERS PRELBR PT PLAB PP PAK PDEM PKPA PSOCI PF PLO PTERM PJUS PSOE PELOSI PROPERTY PGOVPREL PARP PRL PNIR PHUMKPAL PG PREZ PGIC PBOV PAO PKK PROV PHSAK PHUMPREL PROTECTION PGOVBL PSI PRELPK PGOVENRG PUM PRELKPKO PATTY PSOC PRIVATIZATION PRELSP PGOVEAIDUKNOSWGMHUCANLLHFRSPITNZ PMIG PREC PAIGH PROG PSHA PARK PETER POG PHUS PPREL PS PTERPREL PRELPGOV POV PKPO PGOVECON POUS PGOVPRELPHUMPREFSMIGELABEAIDKCRMKWMN PWBG PMAR PREM PAR PNR PRELPGOVEAIDECONEINVBEXPSCULOIIPBTIO PARMIR PGOVGM PHUH PARTM PN PRE PTE PY POLUN PPEL PDOV PGOVSOCI PIRF PGOVPM PBST PRELEVU PGOR PBTSRU PRM PRELKPAOIZ PGVO PERL PGOC PAGR PMIN PHUMR PVIP PPD PGV PRAM PINL PKPAL PTERE PGOF PINO PHAS PODC PRHUM PHUMA PREO PPA PEPFAR PGO PRGOV PAC PRESL PORG PKFK PEPR PRELP PREFA PNG PGOVPHUMKPAO PRELECON PINOCHET PFOR PGOVLO PHUMBA PRELC PREK PHUME PHJM POLINT PGOVPZ PGOVKCRM PGOVE PHALANAGE PARTY PECON PEACE PROCESS PLN PRELSW PAHO PEDRO PRELA PASS PPAO PGPV PNUM PCUL PGGV PSA PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PGIV PRFE POGOV PEL PBT PAMQ PINF PSEPC POSTS PHUMPGOV PVOV PHSAPREL PROLIFERATION PENA PRELTBIOBA PIN PRELL PGOVPTER PHAM PHYTRP PTEL PTERPGOV PHARM PROTESTS PRELAF PKBL PRELKPAO PKNP PARMP PHUML PFOV PERM PUOS PRELGOV PHUMPTER PARAGRAPH PERURENA PBTSEWWT PCI PETROL PINSO PINSCE PQL PEREZ PBS

Browse by classification

Community resources

courage is contagious

Viewing cable 06ISTANBUL1209, PRESCRIPTION FOR TURKEY'S PHARMACEUTICALS MARKET

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs

Understanding cables
Every cable message consists of three parts:
  • The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
  • The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
  • The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
To understand the justification used for the classification of each cable, please use this WikiSource article as reference.

Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06ISTANBUL1209.
Reference ID Created Released Classification Origin
06ISTANBUL1209 2006-07-03 14:13 2011-08-24 01:00 UNCLASSIFIED//FOR OFFICIAL USE ONLY Consulate Istanbul
null
Dianne Wampler  07/05/2006 04:18:21 PM  From  DB/Inbox:  Dianne Wampler

Cable 
Text:                                                                      
                                                                           
      
UNCLAS    SENSITIVE     ISTANBUL 01209

SIPDIS
CX:
    ACTION: ECON
    INFO:   CONS PA RAO FAS MGT PMA FCS POL DCM AMB

DISSEMINATION: ECON /1
CHARGE: PROG

VZCZCAYO508
RR RUEHAK
DE RUEHIT #1209 1841413
ZNR UUUUU ZZH
R 031413Z JUL 06
FM AMCONSUL ISTANBUL
TO RUEHC/SECSTATE WASHDC 5397
INFO RUEHAK/AMEMBASSY ANKARA 5305
RUEHDA/AMCONSUL ADANA 2232
RUCPDOC/DEPT OF COMMERCE WASHDC
RHEHNSC/NSC WASHDC
UNCLAS ISTANBUL 001209 
 
SIPDIS 
 
SENSITIVE 
 
DEPARTMENT FOR EUR/SE 
COMMERCE FOR CRUSNACK 
DEPARTMENT PASS USTR FOR LERRION 
 
E.O. 12958: N/A 
TAGS: ETRD EINV PGOV TU
SUBJECT: PRESCRIPTION FOR TURKEY'S PHARMACEUTICALS MARKET 
 
 
1.  (SBU)  Summary.  At a June 9 meeting in Istanbul, 
American pharmaceutical company directors expressed 
satisfaction that Turkey remained on the 2006 Special 301 
Priority Watch List but told Ambassador Wilson that 
inadequate patent protection and an absence of transparency 
in the GOT,s health bureaucracy continue to stymie U.S. 
market access.  Current facilitator for the Local American 
Working Group (LAWG) and Merck Director Jeff Kemprecos argued 
that the GOT,s continued reimbursement of medical costs 
related to "over the counter" generic remedies, including 
gingko products, was costing the GOT about USD 50 million a 
year and effectively limiting patient access to more 
effective innovative medicines.  At the same time, Kemprecos 
said, Turkey spent less per capita on pharmaceuticals than 
its European comparator countries.  A shift in GOT practices, 
he suggested, could result in significant additional foreign 
investment in Turkey, along the lines of the "Irish miracle," 
with U.S. companies choosing to produce drugs here.  End 
summary. 
 
2.  (SBU)  Managing directors and representatives of 
Schering-Plough, Merck Sharp & Dohme, Pfizer, Johnson & 
Johnson, Lilly, Bristol-Myers Squibb, Abbott, Pfizer and 
Wyeth Laboratories discussed with Ambassador Wilson the 
challenges facing American pharmaceutical companies in 
Turkey, including IPR violations and potential molecular 
theft, the absence of regulatory transparency and efficiency, 
and unfair competitive practices and limited patient access 
to innovative medicines due to lack of funding.  Despite 
steady growth in the dollar value of all OTC and prescription 
medicines sold in Turkey over ten years, LAWG facilitator 
Jeff Kemprecos said these issues continue to thwart industry 
growth in Turkey. 
 
 3.  (SBU)  Lilly Managing Director Jeremy Morgan asked that 
the United States continue to use its diplomatic leverage 
with Turkey to press for improvement in IPR protection, 
regulatory transparency, and the dropping of arbitrary 
restrictions in manufacturing, noting that this could lead to 
major pharmaceutical investment capital for Turkey.  Citing 
the Irish example, Morgan and Kemprecos argued that Turkey 
has the potential to become a major manufacturing point for 
European and Middle East markets.  As it was, some of the 
problems in the Turkish pharmaceuticals market lead directly 
to the loss of USD 50 million annually in health care 
expenditures on useless product.  A shift to innovative and 
proven prescription drugs, they said, is in the long-term 
interest not only of patient health, but of controlling 
health care costs. 
 
4.  (SBU)  Ambassador Wilson noted the importance of staying 
the course on Turkey,s macro-economic progress and the need 
to implement further economic reforms; one of the IMF,s 
areas for improvement had been Turkey,s subsidies for 
consumer health expenditures.  He added that part of the U.S. 
approach on issues of importance to the pharmaceutical 
industry would be to work closely with the Europeans. 
 
5. (SBU)  Ambassador also explained the mission's efforts on 
behalf of U.S. pharmaceutical companies in Turkey. 
Currently, embassy officials are working closely with their 
EU counterparts to coordinate our messages about the 
importance of data protection.  In addition to frequent 
meetings with the MOH, who has ultimate control over data 
protection and pricing and reimbursement decisions, we also 
discuss the issue periodically with officials from the 
Foreign Trade Undersecretariat (FTU), who is responsible for 
ensuring that Turkey meets its international, including WTO 
and TRIPS, obligations.  We are currently supporting a 
dialogue between company representatives and FTU officials 
that would not only provide the opportunity to discuss their 
concerns but also to present their vision for enhanced 
investment in Turkey if these problems are eliminated.  At 
the same time, Ambassador alsocautioned that Turkey has 
already entered a pre-election political mode; as in the 
U.S., governments during these periods are often distracted 
or focused on addressing constituent demands.  The Ambassador 
counseled the pharmaceutical directors to position their 
companies and industry now for post-election progress in a 
more pragmatic political atmosphere. 
 
JONES 
JONES